J Bradley Layton1,2, Anne M Butler3,4, Catherine A Panozzo5, M Alan Brookhart1. 1. Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Research Triangle Park, North Carolina. 2. RTI Health Solutions, Research Triangle Park, North Carolina. 3. Division of Infectious Diseases, Washington University School of Medicine in St. Louis, St. Louis, Missouri. 4. Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri. 5. Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: The aim of this study was to evaluate the short-term risk of adverse events associated with rotavirus vaccine (RV) in infants, overall and by vaccine formulation (three-dose pentavalent, RV5; two-dose monovalent, RV1). METHODS: We identified US newborns with commercial insurance during 2006-2014 receiving a diphtheria-tetanus-pertussis vaccine (DTaP) dose and assessed if RV was administered concurrently. We followed infants for 30 days after each dose for diagnoses of intussusception, other gastrointestinal events, seizures, Kawasaki disease, thrombocytopenia, otitis media, all-cause emergency department visits, and all-cause hospitalisations. We estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) with multivariable Cox proportional hazards models comparing: (a) those receiving DTaP+RV vs those receiving DTaP alone; and (b) RV5 vs RV1. Analyses were performed separately within DTaP doses and then meta-analysed across doses. RESULTS: We identified 1 031 431 first DTaP doses, 821 833 second doses, and 615 293 third doses; 79.2% had a concurrent RV, 94.1% of which were RV5. Absolute risks of serious outcomes were very low. Compared to infants who received DTaP alone, infants who received RV+DTaP did not experience consistently increased risk of intussusception (hazard ratio [HR] 1.13, 95% confidence interval [CI] 0.68, 1.88) or any other outcome except for otitis media after dose 2: HR 1.11, 95% CI 1.08, 1.15. This increased otitis media risk was not as pronounced in RV5 when comparing RV5 to RV1; HR 0.92, 95% CI 0.89, 0.95. CONCLUSIONS: These data were not consistent with an increased risk of intussusception or other adverse events following vaccination with RV, except potentially for a small increased risk of otitis media, particularly in RV1.
BACKGROUND: The aim of this study was to evaluate the short-term risk of adverse events associated with rotavirus vaccine (RV) in infants, overall and by vaccine formulation (three-dose pentavalent, RV5; two-dose monovalent, RV1). METHODS: We identified US newborns with commercial insurance during 2006-2014 receiving a diphtheria-tetanus-pertussis vaccine (DTaP) dose and assessed if RV was administered concurrently. We followed infants for 30 days after each dose for diagnoses of intussusception, other gastrointestinal events, seizures, Kawasaki disease, thrombocytopenia, otitis media, all-cause emergency department visits, and all-cause hospitalisations. We estimated adjusted hazard ratios (HR) and 95% confidence intervals (CI) with multivariable Cox proportional hazards models comparing: (a) those receiving DTaP+RV vs those receiving DTaP alone; and (b) RV5 vs RV1. Analyses were performed separately within DTaP doses and then meta-analysed across doses. RESULTS: We identified 1 031 431 first DTaP doses, 821 833 second doses, and 615 293 third doses; 79.2% had a concurrent RV, 94.1% of which were RV5. Absolute risks of serious outcomes were very low. Compared to infants who received DTaP alone, infants who received RV+DTaP did not experience consistently increased risk of intussusception (hazard ratio [HR] 1.13, 95% confidence interval [CI] 0.68, 1.88) or any other outcome except for otitis media after dose 2: HR 1.11, 95% CI 1.08, 1.15. This increased otitis media risk was not as pronounced in RV5 when comparing RV5 to RV1; HR 0.92, 95% CI 0.89, 0.95. CONCLUSIONS: These data were not consistent with an increased risk of intussusception or other adverse events following vaccination with RV, except potentially for a small increased risk of otitis media, particularly in RV1.
Authors: Patricia Mona Eng; T Christopher Mast; Jeanne Loughlin; C Robin Clifford; Judy Wong; John D Seeger Journal: Pediatr Infect Dis J Date: 2012-03 Impact factor: 2.129
Authors: Veena Hoffman; Nicholas J Everage; Scott C Quinlan; Kathleen Skerry; Daina Esposito; Nicolas Praet; Dominique Rosillon; Crystal N Holick; David D Dore Journal: Pharmacoepidemiol Drug Saf Date: 2016-09-13 Impact factor: 2.890
Authors: Eric S Weintraub; James Baggs; Jonathan Duffy; Claudia Vellozzi; Edward A Belongia; Stephanie Irving; Nicola P Klein; Jason M Glanz; Steven J Jacobsen; Allison Naleway; Lisa A Jackson; Frank DeStefano Journal: N Engl J Med Date: 2014-01-14 Impact factor: 91.245
Authors: W Katherine Yih; Tracy A Lieu; Martin Kulldorff; David Martin; Cheryl N McMahill-Walraven; Richard Platt; Nandini Selvam; Mano Selvan; Grace M Lee; Michael Nguyen Journal: N Engl J Med Date: 2014-01-14 Impact factor: 91.245
Authors: John B Carlin; Kristine K Macartney; Katherine J Lee; Helen E Quinn; Jim Buttery; Ruth Lopert; Julie Bines; Peter B McIntyre Journal: Clin Infect Dis Date: 2013-08-26 Impact factor: 9.079
Authors: Tal Marom; Alai Tan; Gregg S Wilkinson; Karen S Pierson; Jean L Freeman; Tasnee Chonmaitree Journal: JAMA Pediatr Date: 2014-01 Impact factor: 16.193
Authors: Catherine A Panozzo; Sylvia Becker-Dreps; Virginia Pate; Michele Jonsson Funk; Til Stürmer; David J Weber; M Alan Brookhart Journal: PLoS One Date: 2013-09-16 Impact factor: 3.240
Authors: Natália Gibim Mellone; Marcus Tolentino Silva; Mariana Del Grossi Paglia; Luciane Cruz Lopes; Sílvio Barberato-Filho; Fernando de Sá Del Fiol; Cristiane de Cássia Bergamaschi Journal: Front Pharmacol Date: 2019-09-24 Impact factor: 5.810
Authors: Tiphanie P Vogel; Karina A Top; Christos Karatzios; David C Hilmers; Lorena I Tapia; Pamela Moceri; Lisa Giovannini-Chami; Nicholas Wood; Rebecca E Chandler; Nicola P Klein; Elizabeth P Schlaudecker; M Cecilia Poli; Eyal Muscal; Flor M Munoz Journal: Vaccine Date: 2021-02-25 Impact factor: 3.641